HPRA Drug Safety Newsletter Edition 85

Download: hpra-drug-safety-newsletter-edition-85.pdf 303 KB

 The 85th edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

Daclizumab (Zinbryta) and the risk of severe liver injury. EU wide review concludes and confirms further restrictions to reduce risk of liver damage.

New contraindication for injectable methylprednisolone products containing lactose (Solu-Medrone 40mg/vial) in patients with cows milk allergy.

Warning about the use of Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone or prednisolone. Ongoing clinical trial shows an increased risk of death and fractures.

Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter

« Back